Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Hepatitis C Virus: How Will More Efficacious Direct-Acting Antivirals Influence US Prescribing and Reimbursement for This Dynamic Indication? | Physician & Payer Forum | US | 2014
The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate the virus from the patient’s body and thereby reduce or halt the progression of liver fibrosis, preventing further…
Anti-VEGF Agents: How Does Cost Versus Dosing Impact the Wet AMD Treatment Algorithm Among Retinal Specialists in the United States? | Physician & Payer Forum | US | 2014
While Genentech’s Lucentis continues to be the gold-standard treatment for wet age-related macular degeneration (AMD) in the United States, off-label use of Genentech’s Avastin (often…
What Are the U.S. Market Access and Prescribing Hurdles for the Growing Number of LAMA- and LABA-Containing Competitors in the COPD Market? | Physician & Payer Forum | US | 2014
The U.S. market for chronic obstructive pulmonary disease (COPD) therapies consists entirely of symptomatic treatments, namely bronchodilators and anti-inflammatory agents, which improve patients…
Digital Marketing in 2015: Why and How Pharma Must Harness a More Strategic Approach
For digital marketing to truly deliver on its potential, most pharmas have to face and fix four interrelated issues. The first has to do with reforming the organizational structure of marketing and…
Shifts in the U.S. Rheumatoid Arthritis Market Access Landscape Due to Oral Kinase Inhibitors, New Biologics, and Biosimilars: Insights from Payers and Physicians | Physician & Payer Forum | US | 2014
The entrenched positioning of biologics (in particular, tumor necrosis factor-alpha [TNF-alpha] inhibitors) to treat moderate to severe rheumatoid arthritis (RA) has generated a multibillion-dollar…
Beyond Positive Symptoms: How Receptive Are U.S. Psychiatrists and Payers to Therapies Targeting Negative or Cognitive Symptoms of Schizophrenia? | Physician & Payer Forum | US | 2014
Schizophrenia is an often disabling psychiatric disease whose core treatment consists of up to a lifetime of treatment with antipsychotics (older typical antipsychotics or newer atypical…
What Market Access Challenges and Opportunities Lie Ahead for Emerging SLE Biologics? | Physician & Payer Forum | EU5 | 2014
Benlysta (GlaxoSmithKline) is not only the first drug approved for systemic lupus erythematosus (SLE) in more than 50 years, but also the first biologic approved for the indication. However, uptake…
